Up&Up Allergy Relief 180mg Tablets Recalled for Failed Impurity Specification
Perrigo Company PLC is recalling up&up allergy relief fexofenadine hydrochloride 180mg tablets distributed nationwide because stability testing found impurity A exceeded specifications. The affected products are 15-count and 30-count bottles with specific lot numbers and expiration dates.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall. The source text states only that impurity specifications were failed during stability testing with no reported illnesses or injuries. There is no indication of known harm or high-risk contamination. This qualifies as a moderate precautionary recall based on the failed specifications and Class II classification.
Plain-English summary
Perrigo Company PLC is recalling up&up allergy relief, fexofenadine hydrochloride tablets, 24-hour, 180mg antihistamine. The recall involves approximately 7,272 containers distributed nationwide in the USA. The products were made in the Czech Republic and distributed by Target Corp. (Minneapolis, MN).
The recall was initiated because stability testing found that impurity A in the tablets did not meet specification requirements. Specifically, an out-of-specification result for impurity A was obtained during stability testing.
Two packaging configurations are affected: (a) 15-count bottles with lot number 1AE2334, expiration 02/28/2022, NDC 11673-571-22, UPC 3 70030 62303 7; and (b) 30-count bottles with lot number 1BR0462, expiration 10/31/2022, NDC 11673-571-39, UPC 3 70030 62301 3.
Consumers who have purchased these products should stop using them and consult their healthcare provider if they have questions or concerns.
The recalled product
- Product
- up&up allergy relief, Fexofenadine Hydrochloride tablets, 24HR, 180mg/antihistamine, packaged as a) 15 count bottle, NDC 11673-571-22 UPC 3 70030 62303 7; b) 30 count bottle, NDC 11673-571-39 UPC 3 70030 62301 3; Distributed by Target Corp., Mpls., MN 55403, Made in the Czech Re
- Manufacturer
- Perrigo Company PLC
- Affected units
- 7,272
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot a) 1AE2334
- Exp 02/28/2022
- b) 1BR0462
- Exp 10/31/2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 30 recalled by Perrigo Company PLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 30 products in this recall →Related recalls
Same manufacturer · Perrigo Company PLC
See all →- ModerateCareOne Severe Congestion Nasal Spray Recalled Due to Contaminated Excipient
FDA (Drugs) · 2022-03-02
- ModerateEquate Children's Pain and Fever Acetaminophen Suspension Recall
FDA (Drugs) · 2022-03-02
- ModerateEqualine Nasal Oxymetazoline HCl Nasal Spray Recalled for Contaminated Excipient
FDA (Drugs) · 2022-03-02
- ModerateUP AND UP Childrens Acetaminophen Recall Due to Contaminated Excipient
FDA (Drugs) · 2022-03-02
- ModerateCVS Infant's Grape Acetaminophen Suspension Recalled for Contaminated Excipient
FDA (Drugs) · 2022-03-02
Same hazard · impurity degradation
See all →- Low
- ModerateEsomeprazole Magnesium oral suspension recalled for failed impurity specifications
FDA (Drugs) · 2025-05-28
- HighDiltiazem Hydrochloride extended-release capsules recalled due to failed quality specifications
FDA (Drugs) · 2023-02-08
- ModerateXiidra ophthalmic solution recalled for failed impurity and degradation specifications
FDA (Drugs) · 2022-06-15
- ModerateXiidra Ophthalmic Solution Recalled for Failed Impurity and Degradation Specifications
FDA (Drugs) · 2022-06-15